Hereditary Paraganglioma Pheochromocytoma Syndrome

• Hereditary Paraganglioma Pheochromocytoma Syndrome (HPP) is a rare genetic disorder causing tumors in the nervous system.
• It is primarily caused by mutations in succinate dehydrogenase (SDH) genes, making it a hereditary condition.
• Symptoms often include high blood pressure, headaches, and sweating due to hormone overproduction by the tumors.
• Diagnosis involves genetic testing, biochemical tests for hormone levels, and imaging scans.
• Treatment typically focuses on surgical removal of tumors, with ongoing monitoring essential due to the potential for recurrence or new tumor development.

What is Hereditary Paraganglioma Pheochromocytoma?

Hereditary Paraganglioma Pheochromocytoma Syndrome (HPP) is a complex inherited disorder predisposing individuals to develop tumors in various parts of the body. These tumors are primarily paragangliomas, which arise from neural crest cells outside the adrenal glands, and pheochromocytomas, which develop specifically in the adrenal medulla. Both types of tumors can secrete catecholamines, hormones like adrenaline and noradrenaline, leading to a range of symptoms.

The prevalence of hereditary forms of pheochromocytoma and paraganglioma is significant, with estimates suggesting that up to 30-40% of all cases may be hereditary, according to the National Cancer Institute. Understanding what is hereditary paraganglioma syndrome is crucial, as it refers to a group of genetic conditions that specifically lead to the formation of paragangliomas, with or without associated pheochromocytomas, often linked to mutations in the succinate dehydrogenase (SDH) genes.

Symptoms, Causes, and Diagnosis

The manifestations of HPP can vary widely, depending on the location and hormonal activity of the tumors. When tumors produce catecholamines, individuals may experience a characteristic set of symptoms. Recognizing hereditary paraganglioma pheochromocytoma symptoms is vital for early detection and management.

Common symptoms include:

• Persistent or paroxysmal hypertension (high blood pressure)
• Headaches, often severe and throbbing
• Excessive sweating
• Palpitations or rapid heart rate
• Anxiety or panic attacks
• Tremors
• Pallor (pale skin)
• Weight loss

The primary causes and diagnosis of hereditary paraganglioma involve genetic factors. HPP is predominantly caused by germline mutations in the succinate dehydrogenase (SDH) genes, specifically SDHA, SDHB, SDHC, SDHD, and SDHAF2. These genes play a critical role in cellular metabolism and energy production. Mutations in these genes disrupt normal cell function, leading to uncontrolled cell growth and tumor formation. The pattern of inheritance is typically autosomal dominant, meaning only one copy of the mutated gene is needed to increase the risk of developing the syndrome.

Diagnosis involves a multi-faceted approach. Biochemical tests measure catecholamine levels and their metabolites (metanephrines and normetanephrines) in blood plasma or 24-hour urine samples. Imaging studies, such as MRI, CT scans, and specialized nuclear medicine scans (e.g., MIBG scintigraphy or PET scans), are used to locate tumors. Genetic testing confirms the presence of SDH gene mutations, which is crucial for family screening and long-term management strategies.

Treatment for Hereditary Paraganglioma

The management of HPP requires a comprehensive and multidisciplinary approach. The primary goal of hereditary paraganglioma pheochromocytoma treatment is to remove the tumors and manage any associated symptoms, particularly those related to catecholamine excess. Surgical resection is the cornerstone of treatment for localized tumors.

Before surgery for hormonally active tumors, patients typically undergo a period of alpha-blockade medication to control blood pressure and prevent hypertensive crises during the procedure. For tumors that are inoperable, metastatic, or recurrent, other treatment modalities may be considered. These can include radiation therapy, chemotherapy, or targeted therapies, although these are often reserved for specific cases. Lifelong surveillance is essential for individuals with HPP due to the risk of developing new tumors or recurrence. This typically involves regular biochemical screening and imaging to monitor for tumor growth or new lesions.